Tychan, a Singapore-based clinical-stage biotechnology company, is initiating Phase 1 clinical trials to evaluate TY027, the first novel monoclonal antibody (mAb) that specifically targets SARS-CoV-2, the virus that causes COVID-19.
NIH
Copyright © 2014 (MIT Center for Environmental Health Sciences)
Funded by NIH-NIEHS Core Center Grant P30-ES002109
Accessibility
Funded by NIH-NIEHS Core Center Grant P30-ES002109
Accessibility
CENTER FOR ENVIRONMENTAL HEALTH SCIENCES
Massachusetts Institute of Technology | 77 Massachusetts Ave | Building 56-265 | Cambridge, MA 02139
Phone: 617-452-2072 | Fax: 617-452-2066 | cehs@mit.edu